These observations were made based on EKGs from patients who received doses of ARQ 171 from 380 to 760 milligrams per meter squared.
QTc prolongation is a disorder that can result in an irregular heartbeat and is associated with increased risk of sudden cardiac death.
The company is currently reviewing EKGs from patients previously treated at lower doses. Upon completion of this review, the company will make a further decision about continuing this dose escalation trial. The company expects the analysis of QTc prolongation data to be complete between the end of 2007 and early 2008.